Loading...
Market
What will be the total payout from Organon to Dermavant by end of 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $799 million • 25%
$800 million to $1 billion • 25%
More than $1 billion • 25%
Company financial statements and press releases
Story
Organon to Acquire Dermavant for Up to $1.2 Billion with $175 Million Upfront
Sep 18, 2024, 01:15 PM
Organon has announced its acquisition of Dermavant Sciences, a subsidiary of Roivant Sciences, in a deal valued at up to $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The terms of the deal involve an upfront payment of $175 million, with additional payments contingent on regulatory approval and sales milestones, potentially reaching a total of $1.2 billion. This includes $75 million on approval in AtD. Roivant's stock rose by 2.2% pre-market following the announcement. This strategic move is seen as positive for Roivant, while analysts have mixed opinions on its impact on Organon.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Yes • 50%
No • 50%
Alopecia treatment • 25%
Psoriasis treatment • 25%
Eczema treatment • 25%
Other • 25%
None • 25%
Up to $200 million • 25%
$200 million to $600 million • 25%
Above $600 million • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Neutral • 25%
Up to $150 million • 25%
$150 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Less than $25 • 25%
$25 to $29.99 • 25%
$30 to $34.99 • 25%
$35 or more • 25%